Determinants of outcome in patients eligible for thrombolysis for ischemic stroke

Vascular Health and Risk Management

Volumn 3, Issue 5, 2007, Pages 749-754

  Caso, Valeria ^a   Paciaroni, Maurizio ^a   Venti, Michele ^a   Palmerini, Francesco ^a   Silvestrelli, Giorgio ^a   Milia, Paolo ^a   Biagini, Sergio ^a   Agnelli, Giancarlo ^a  

^a Ospedale Silvestrini   (Italy)

Author keywords

Carotid artery occlusion; Diabetes; Outcome; Stroke; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; DEATH; DIABETES MELLITUS; DISABILITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; RANKIN SCALE; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 36148999769     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. 1993. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 24:35-41.
2. Albers GW, Bates VE, Clark WM, et al. 2000. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA, 283:1145-50.
3. Arnold M, Nedeltchev K, Sturzenegger M, et al. 2002. Thrombolysis in patients with acute stroke caused by cervical artery dissection: analysis of 9 patients and review of the literature. Arch Neurol, 59:549-53.
4. Bruno A, Levine SR, Frankel MR, et al. NINDS rt-PA Stroke Study Group. 2002. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology, 59:669-74.
5. Clark WM, Wissman S, Albers GW, et al. 1999. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Non-interventional Therapy in Ischemic Stroke. JAMA, 282:2019-26.
6. Demchuk AM, Tanne D, Hill MD, et al. 2001. Predictors of good outcome after intravenous t-PA for acute ischemic stroke. Neurology, 57:474-80.
7. Del Zoppo GP, Poeck K, Pessin AJ. 1992. Recombinant intravenous plasminogen activitor in acute thrombotic; and embolic stroke. Ann Neurol, 32:78-86.
8. European Stroke Initiative recommendations for stroke management. European Stroke Council, European Neurological Society and European Federation of Neurological Societies. 2000. Cerebrovasc Dis, 10:335-51.
9. European Stroke Initiative recommendations for stroke management- update 2003. Cerebrovasc Dis, 16:311-37.
10. Goldstein LB, Bertels C, Davis JN. 1989. Interrater reliability of the NIH Stroke Scale. Arch Neurol, 46:660-2.
11. Grond M, Stenzel C, Schmulling S, et al. 1998. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke, 29:1544-9.
12. Hacke W, Kaste M, Fieschi C, et al. 1995. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study. JAMA, 274:1017-25.
13. Hacke W, Schwab S, Horn M, et al. 1996. Malignant middle cerebral artery territory infarction. Arch Neurol, 53:309-315.
14. Hacke W, Kaste M, Fieschi C, et al. 1998. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet, 352:1245-51.
15. Hacke W, Brott T, Caplan L, et al. 1999. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology, 53:S3-14.
16. Hacke W, Donnan G, Fieschi C, et al. 2004. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, 363:768-74.
17. Henon H, Godefroy O, Leys D, et al. 1995. Early predictors of death after acute cerebral ischemic events. Stroke, 26:392-8.
18. Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. 2004. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA, 292:1831-8.
19. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. 2005. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ, 172:1307-12.
20. Leys D, Pruvo JP, Petit H, et al. 1989. Maladie d'Alzheimer, analyse statistique des resultats du scanner X. Rev Neurol, 145:134-9.
21. Linfante I, Llinas RH, Selim M, et al. 2002. Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusion after intravenous tissue plasminogen activator. Stroke, 33:2066-71.
22. Mori E, Yoneda Y, Tabuchi M, et al. 1992. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology, 976-82.
23. Mouradian MS, Senthilselvan A, Jickling G, et al. 2005. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry, 76:1234-7.
24. Pexman JH, Barber PA, Hill MD, et al. 2001. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol, 22:1534-42.
25. Rudolf J, Neveling K Grond M, et al. 1999. Stroke following internal carotid artery occlusion - a contra-indication for intravenous thrombolysis? Eur J Neurol, 6:51-5.
26. Sarti C, Stegmayr B, Tolonen H, et al. 2003. Are changes in mortality from stroke caused by changes in stroke event rates or case fatality? Results from the WHO MONICA Project. Stroke, 34:1833-40.
27. Saposnik G, Young B, Silver B, et al. 2004. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome. JAMA, 292:1839-44.
28. Schellinger PD, Fiebach JB, Mohr A, et al. 2001. Thrombolytic therapy for ischemic stroke - a review. Part I - Intravenous thrombolysis. Crit Care Med, 29:1812-18.
29. Sylaja PN, Cote R, Buchan AM, et al. Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. 2006. Thrombolysis in patients older than 80 years with acute ischemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry, 77:826-9.
30. Tanne D, Gorma MJ, Bates VE, et al. 2000. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older. The t-PA Stroke Survey Experience. Stroke, 31:370-5.
31. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 1995 Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 333:1581-7.
32. Trouillas P, Nighoghossian N, Derex L, et al. 1998. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke, 29:2529-40.
33. van Swieten JC, Koudstaal PJ, Visser MC, et al. 1988. Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19:604-7.
34. Weimar C, Ziegler A, Konig IR, et al. 2002. Predicting functional outcome and survival after acute ischemic stroke. J Neurol, 249:888-95.
35. WHO Guidelines Subcommittee. 1999. World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens, 17:151-83.